Development and characterisation of a cyclophosphamide resistant variant of the BNML rat model for acute myelocytic leukaemia.
A cyclophosphamide resistant subline (BNML/CPR) was developed in vivo in the BN rat acute myelocytic leukaemia (BNML) model. Full resistance was achieved after in vivo exposure of leukaemic animals to cyclophosphamide with, in total, 15 intraperitoneal injections of 100 mg/kg. The CPR line was cross-resistant to ifosfamide, but less so to mafosfamide. Continuous transplantation of the BNML/CPR line without a cyclophosphamide selection pressure resulted in the emergence of a subline (BNML/CPR greater than S) whose sensitivity to cyclophosphamide was similar to that of the parent BNML/S line. Both in the BNML parent line and in the BNML/CPR greater than S line, a 2p+ marker chromosome was present, whereas a 2p+q+ marker chromosome was characteristic for the BNML/CPR line. The mechanism of cyclophosphamide resistance can now be investigated in the BNML model at the DNA, at the mRNA and at the protein level.
Martens
A C
AC
Institute for Applied Radiobiology and Immunology/TNO, Rijswijk, The Netherlands.
de Groot
C J
CJ
Hagenbeek
A
A
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002460:Cell Line; D003520:Cyclophosphamide / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D007069:Ifosfamide / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D014411:Neoplastic Stem Cells / Q000187:drug effects; D051381:Rats; D011914:Rats, Inbred BN
D000970:Antineoplastic Agents; C048341:mafosfamide; D003520:Cyclophosphamide; D007069:Ifosfamide